FDA Releases Rules for Biosimilar Product Promotion Guidance
Published Date: 12/10/2025
Notice
Summary
The FDA just released clear rules for companies on how to advertise and label prescription biological drugs, including biosimilars and interchangeable biosimilars. This helps drug makers know what’s allowed when promoting these products, making sure info is honest and easy to understand. The new guidance is official as of December 10, 2025, so affected companies should update their ads soon to avoid any hiccups.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
New FDA Ad Rules for Biologics
On December 10, 2025, FDA issued final guidance on promotional labeling and advertising for prescription reference biological products, biosimilar products, and interchangeable biosimilar products. The guidance tells firms how to identify products, present study information, present data not in FDA-approved labeling (when consistent with labeling), compare biosimilars and reference products, and submit promotional communications to FDA; the recommendations apply regardless of medium (paper or digital).
Pharmacy Substitution Clarified
The guidance reiterates that an interchangeable biosimilar product may be substituted for the reference product without the prescribing healthcare provider's intervention (section 351(i)(3) of the Public Health Service Act). Decisions about pharmacy-level substitution remain subject to State pharmacy law.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-22426, Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 9, 2026, to make sure the process is clear, useful, and not too much work. This helps CMS do its job better without wasting anyone’s time or money.
Next: 2025-22428, Determination Pursuant to Section 102 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, as Amended
Starting December 10, 2025, the Department of Homeland Security is speeding up the building of barriers and roads along the Texas border by temporarily skipping some usual rules and laws. This move helps stop illegal crossings and keeps the country safer, focusing on quick action without delays. It affects border communities and aims to boost security without mentioning extra costs or funding changes.